1. Home
  2. PUMP vs TBPH Comparison

PUMP vs TBPH Comparison

Compare PUMP & TBPH Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo ProPetro Holding Corp.

PUMP

ProPetro Holding Corp.

HOLD

Current Price

$14.90

Market Cap

1.0B

Sector

Energy

ML Signal

HOLD

Logo Theravance Biopharma Inc.

TBPH

Theravance Biopharma Inc.

HOLD

Current Price

$16.74

Market Cap

824.9M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
PUMP
TBPH
Founded
2007
2013
Country
United States
United States
Employees
N/A
N/A
Industry
Oilfield Services/Equipment
Biotechnology: Pharmaceutical Preparations
Sector
Energy
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
1.0B
824.9M
IPO Year
2017
2013

Fundamental Metrics

Financial Performance
Metric
PUMP
TBPH
Price
$14.90
$16.74
Analyst Decision
Buy
Buy
Analyst Count
7
6
Target Price
$14.14
$18.40
AVG Volume (30 Days)
5.3M
326.3K
Earning Date
04-30-2026
05-04-2026
Dividend Yield
N/A
N/A
EPS Growth
100.76
279.13
EPS
N/A
N/A
Revenue
$1,269,158,000.00
$15,386,000.00
Revenue This Year
N/A
$8.46
Revenue Next Year
$15.61
N/A
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$4.51
$10.56
52 Week High
$18.50
$21.03

Technical Indicators

Market Signals
Indicator
PUMP
TBPH
Relative Strength Index (RSI) 43.24 57.26
Support Level $13.88 $16.07
Resistance Level $15.34 $17.21
Average True Range (ATR) 0.82 0.32
MACD -0.11 0.07
Stochastic Oscillator 26.33 94.57

Price Performance

Historical Comparison
PUMP
TBPH

About PUMP ProPetro Holding Corp.

ProPetro Holding Corp is a Texas-based oilfield services company. It provides hydraulic fracturing, wireline, and other complementary services to oil and gas companies engaged in the exploration and production of North American oil and natural gas resources. The company focused on the Permian Basin. The operating segments of the company are hydraulic fracturing which generates key revenue, wireline, cementing, and power generation service.

About TBPH Theravance Biopharma Inc.

Theravance Biopharma Inc is a biopharmaceutical company focused on the development and commercialization of medicines to improve patients lives. The company leverages decades of expertise and has developed FDA-approved YUPELRI (revefenacin) inhalation solution for the maintenance treatment of patients with COPD. Its ampreloxetine Phase 3 clinical study (CYPRESS) for the treatment of symptomatic neurogenic orthostatic hypotension in patients with multiple system atrophy did not meet its primary endpoint. The company operates in a single segment, the development and commercialization of human therapeutics, and operates in the United States, which generates maximum revenue, and Europe.

Share on Social Networks: